The Phase 3 Trial Methods Used to Assess Outcomes for Patients With aRCC on Nivolumab Plus Cabozantinib Versus Sunitinib
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how the phase 3 CheckMate 9ER trial was conducted in order to assess the outcomes by baseline disease characteristics for patients with aRCC.
Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).
During this discussion, Apolo explained how the phase 3 CheckMate 9ER trial was conducted in order to assess the outcomes by baseline disease characteristics for patients with aRCC treated with either nivolumab plus cabozantinib or sunitinib.
